phrykt

Protagenic Therapeutics, Inc.new (PTIX): who owns it and who trades it

As of Nov 6, 2026, PTIX insiders reported 7 purchases worth $30.7K in the last 12 months. The largest buyer was Garo H Armen (Chair), with $30.7K.

Latest filing Nov 6, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Insider trades

In the last 12 months, PTIX insiders reported $30.7K of open-market purchases and $0 of sales.

Purchases, 12 months
$30.7K
7 trades, 1 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Aug 21, 2026
Filed Aug 24, 2026

Purchases and sales by month

$25.9K$25.9KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Aug 21, 2026Garo H ArmenChairPurchase20,000$0.65$13KForm 4
Aug 20, 2026Garo H ArmenChairPurchase16,634$0.59$9.8KForm 4
Aug 19, 2026Garo H ArmenChairPurchase2,700$0.35$945Form 4
Aug 11, 2026Garo H ArmenChairPurchase2,220$0.32$710Form 4
Aug 6, 2026Garo H ArmenChairPurchase685$0.22$151Form 4
Aug 5, 2026Garo H ArmenChairPurchase5,000$0.26$1.3KForm 4
Jul 30, 2026Garo H ArmenChairPurchase26,291$0.18$4.7KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Garo H ArmenEXEC. CHAIR & PRINCIPAL OFF., Director$30.7K–Aug 21, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

PTIX short interest

Low short interest. 0.7% of PTIX shares are sold short: about 1 share in 140. Over the last 12 reports the number of shares short went down 1%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 12,907 PTIX shares were sold short, 0.7% of the shares outstanding, down 0.3% from the report before. At the average daily volume of 1,965 shares, buying them all back would take about 6.6 trading days (days to cover).

Shares short, % of all shares

0.71%May 15Oct 300.73%

Days to cover

6.6May 15Oct 307.4

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202612,9070.71%-0%1,9656.6
Oct 15, 202612,9400.71%-0%2,1825.9
Sep 30, 202612,9690.72%+0%10,9441.2
Sep 15, 202612,9220.71%-1%26,3501.0
Aug 31, 202613,0270.72%-0%80,1451.0
Aug 14, 202613,0580.72%-1%11,7771.1
Jul 31, 202613,1650.73%+0%18,3471.0
Jul 15, 202613,1560.73%+1%31,3421.0
Jun 30, 202613,0210.72%+0%7,8731.6
Jun 15, 202612,9960.72%No change15,8091.0
May 29, 202612,9960.72%No change3,6883.5
May 15, 202612,9960.72%-28%12,1141.1

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Protagenic Therapeutics, Inc.new company events

Protagenic Therapeutics, Inc.new filed 7 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership, listing). The latest was on Nov 6, 2026.

  1. Nov 6, 2026AgreementProtagenic Therapeutics, Inc. issued a promissory note to Patness LLC, pursuant to which the Borrower agreed to pay to the order of the Lender the principal sum of $250,000. Filing
  2. Aug 20, 2026AnnouncementThe Company announced that it has received written responses from the FDA to the Company’s Type B pre-IND meeting request for PT00114, the Company’s lead investigational neuropeptide product candidate targeting the teneurin C-terminal associated peptide pathway, for the treatment of GAD. Based on… Filing
  3. Apr 7, 2026LeadershipThe Board of Directors of Protagenic Therapeutics, Inc. notified Alexander Arrow, MD, the Company’s Chief Financial Officer, that his employment with the Company will be terminated effective April 30, 2026. Filing
  4. Mar 3, 2026LeadershipThe Board of Directors of Protagenic Therapeutics, Inc. appointed William (Bill) Nichols, Jr., age 51, as President of the Company. Filing
  5. Feb 24, 2026DealPursuant to the Unwind Agreement, PTIX disposed of its ownership interest in Phytanix Bio and returned 100% of the issued and outstanding shares of Phytanix Bio to the Former Phytanix Stockholders. Filing
  6. Jan 5, 2026ListingOTC Trading and Next Steps Beginning January 5, 2026, Protagenic Therapeutics, Inc. expects its common stock and warrants to be quoted for trading on the over-the-counter market. Filing
  7. Nov 26, 2025ListingProtagenic Therapeutics, Inc. received a notification letter (the “Notice” ) from the Nasdaq Listing Qualifications Staff (the “Staff” ) indicating that the Company is not in compliance with Nasdaq Listing Rule 5550(b)(1) (minimum stockholders’ equity of $2.5 million) and Nasdaq Listing Rule… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Questions about Protagenic Therapeutics, Inc.new (PTIX) stock

Are PTIX insiders buying or selling?

In the last 12 months, PTIX insiders reported 7 open-market purchases worth $30.7K and no sales. The latest trade was on Aug 21, 2026. See every trade.

What is the short interest in PTIX?

As of Oct 30, 2026, 12,907 PTIX shares were sold short, 0.7% of the shares outstanding, down 0.3% from the report before. At the average daily volume of 1,965 shares, buying them all back would take about 6.6 trading days (days to cover). See the history.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.